

AAI NEWSLETTER

August 1987

AMERICAN ASSOCIATION OF IMMUNOLOGISTS

9650 Rockville Pike
Bethesda, Maryland 20814



President's Message

As The American Association of Immunologists enters its 75th year, I see an active, stable and smoothly functioning organization, with momentum toward some new goals and the apparatus now to handle them. This is largely due to the efforts of my predecessors, most recently Drs. Barry R. Bloom and William E. Paul, and of our Association's former Secretary-Treasurer, Dr. Henry Metzger, and Dr. Joseph F. Saunders, the Association's Executive Officer. I am most grateful to them for the solid and solvent operation I have inherited. Our aim for the coming year will be to maintain the momentum they have fostered. Fortunately for me, and the Council, under our new constitution Past President Bill Paul will continue on the Council, as a voting member, and be available to advise us as we pursue our objectives, many of which he initiated.

To assist us in this, I and the Council welcome its newest member, Dr. Frank W. Fitch, who has so ably represented us for the past three years on the FASEB Public Affairs Committee. And, Dr. Ethan Shevach, the Editor-in-Chief of the JOURNAL OF IMMUNOLOGY is already fully in command of the now Bethesda-based Journal operation. On behalf of the Council, I express sincere gratitude to Dr. Barry R. Bloom, AAI Past President and FASEB's immediate Past President, and JOURNAL OF IMMUNOLOGY Editor-in-Chief, Dr. Joseph D. Feldman. Both are retiring from Council but, we hope, will still be available to advise us.

Several items of Association business warrant mention at this time, and we will keep you updated on them. The Corporate Associate Member program, established by Council and implemented by Dr. Saunders, now totals 25 members, and will prove especially important to us as we organize our 75th Anniversary celebration for next year.


Now that we have our new Central Office well organized at FASEB headquarters and increased computerization for the JOURNAL OF IMMUNOLOGY operation, we are moving to establish a much-needed data base on our membership. This is a development originated by the Committee on the Status of Women which the Council decided to extend to the entire membership. A committee, chaired by Dr. Saunders, is developing a questionnaire which members will be receiving with the autumn dues notices.

You are probably aware that a new Clinical Immunology Society has been formed. The

AAI Council has contributed to the support of the first two conferences of this group and is committed to maintaining a close working relationship with it. A joint committee has been formed to develop plans for such a relationship, to be considered at the autumn meetings of the Councils of the AAI and the Clinical Immunology Society.

Our most important item of business for the coming year will be the celebration of the 75th Anniversary of the Founding of the AAI at the FASEB Annual Meeting in Las Vegas, 1-5 May 1988. A number of special events are being planned, about which we will keep you informed in forthcoming Newsletters and the FASEB Call for Abstracts. The FASEB intersociety THEME Symposium on "Receptors and Growth Factors" is being organized for the AAI by Dr. Joost J. Oppenheim. An attractive program of minisymposia and Plenary Speakers is being developed by the Program Committee, led by Chairman Dr. Richard J. Hodes and Executive Officer Dr. Saunders. On Tuesday, 3 May 1988, a special Celebratory Symposium, "IMMUNOLOGY IN PERSPECTIVE", will be presented, featuring past AAI Presidents Dr. Baruj Benacerraf, Dr. Elvin A. Kabat, Dr. David W. Talmage, Dr. Michael Heidelberger (with whom we will celebrate his 100th birthday), and the IUIS President Sir Gustav J.V. Nossal. An exhibit on the history of the AAI is being planned by a committee led by AAI Historian Dr. Arthur M. Silverstein and Executive Officer Dr. Saunders, whose historical notes in past Newsletters have been most interesting and enlightening. We are seeking to make this meeting a landmark event in the history of the AAI and strongly encourage all members to plan to attend.

Finally, the Council and I welcome any and all suggestions from the membership for improvements in our activities, new opportunities we might be overlooking, and especially for this year, ways in which we might make our 75th anniversary celebration more meaningful.



Donald C. Shreffler, Ph.D.

* The Association gratefully acknowledges its CORPORATE ASSOCIATE MEMBERS for their *
* corporate contributions in immunologic science and the support of new activities *
* and innovations of the Association ABBOTT LABORATORIES, Pharmaceutical *
* Products.... AMERICAN CYANAMID COMPANY, LEDERLE Laboratories.... BEHRING *
* DIAGNOSTICS, Division of American Hoechst Corporation.... BRISTOL-MYERS COMPANY, *
* Pharmaceuticals Division.... CIBA-GIEGY CORPORATION, Pharmaceuticals Division.... *
* EASTMAN KODAK COMPANY, Chemicals Division.... GENZYME CORPORATION.... HOFFMAN *
* LAROCHE INC., Roche Research Institute.... IMCLONE SYSTEMS INCORPORATED.... *
* IMREG, INC.... McNEIL PHARMACEUTICAL.... MONSANTO COMPANY.... ORTHO *
* PHARMACEUTICALS CORPORATION.... PFIZER INC., Pfizer Pharmaceuticals.... PPG *
* INDUSTRIES, INC., Chemicals Group.... THE PROCTER & GAMBLE COMPANY.... RIBI *
* IMMUNOCHEM RESEARCH, INC.... RORER CENTRAL RESEARCH, Rorer Pharmaceutical *
* Corporation.... SANDOZ PHARMACEUTICALS CORPORATION.... SCHERING CORPORATION, *
* Schering-Plough.... SMITHKLINE & FRENCH LABORATORIES.... E.R. SQUIBB & SONS.... *
* TECHNICON INSTRUMENTS CORPORATION, Clinical Diagnostics.... THE UPJOHN *
* COMPANY.... WAVERLY PRESS INC.... As well, we are grateful to our Corporate *
* friends -- E.I. du Pont de Nemours Inc., IMMUNEX Corporation, CISTRON *
* Biotechnology, CETUS Corporation, CYTOGEN Corporation, and SANDOZ for *
* contributions in support of specific 1987 Minisymposia. *

..... CONTENT

President's Message.....

Executive Officer's Notebook.....

Notices of Consequence.....BANNER 1988.....FASEB 1987
Data.....Frederik B. Bang Scholarships

The AAI Governance, 1987-1988

The Constituency Who's Who.....IOM Members.....Awards.....
Achievements.....Beyond the Call.....Members EMERITUS
.....IN MEMORIAM.....

Knowing our Corporate Associates.....

Positions and Opportunities.....NIAID Program Director.....
Cellular Immunologist.....Cancer Prevention FELLOWSHIPS.....

New in Immunology.....REGIONAL IMMUNOLOGY Journal.....The
Association of Medical Laboratory Immunologists.....

From the Allied Sector.....

Off the Literary Shelf.....

Legislative Assets and Liabilities.....

Within the HHS.....

Inside the National Academy.....

International Notes.....

The Immunology Calendar.....

* WANTED..... desperately NEEDED..... VOLUME 1, NUMBER 1 *
* (Single Issue) of the JOURNAL OF IMMUNOLOGY..... *
* REWARD is AAI's absolute gratitude and CITATION in the *
* next issue of the AAI Newsletter!!! *

THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS
THE FIRST 25 YEARS.... 1913-1938

The first endeavor, on 5 May 1913, to organize a society of immunologists was not consummated because of too many "no shows" amongst those who, over the previous year, "expressed willingness to join such a society." However, just six weeks later, on 19 June 1913, the interest, enthusiasm and commitment were manifest among the enrolled CHARTER MEMBERS and The American Association of Immunologists became a reality.

Looking back to the zeal and dedication of the FOUNDERS, we must acknowledge their stature as leaders to whom we can relate a high measure of strength and perseverance toward the evolution and development of the organization and its science as we acknowledge them today. Dr. Martin J. Synnott, he first had the idea in 1912; Dr. Gerald Bertram Webb, he espoused the concept after being approached by Synnott; Dr. Victor C. Vaughan counselled Webb against exclusion of laboratory scientists; and Dr. A. Parker Hitchens was the Councillor with vision transcending a "club-type" organization.

The wisdom and perception of the Founders, and their successors, during the Association's early years were remarkably discerning, in retrospect. If studied in detail, much of the activity during the first twenty-five years might imbue today's immunologists with overtones of deja vu. Indeed, the Founders foresaw the need and value of a firm albeit flexible system of governance promulgated by an encompassing Constitution and Bylaws. They recognized the potential benefit to the organization in growth by attraction of new "eligible" members to the ranks. They were aware of the need for prudent management and fiscal responsibility. They acknowledged the necessity of an annual forum for scientific interaction by the members and the dissemination of research results through the medium of an "official society journal." In that context, they considered outreach and collaboration with other societies of equal importance, even to the point of amalgamation as occurred with the New York Society for Serology and Hematology in 1920. There were occasions when Council had to act dogmatically on issues which could have serious future impact on the Association, its science and others.

Dr. Hitchens and his fellow Councillors worked diligently, for some three years, toward developing the Association's rules for governance. The principles of the Association's Constitution and Bylaws of 1917 are still extant today, even though modified or expanded to accommodate contemporary situations. The first of the major changes occurred in 1936 relative to the composition of the Council and the management of the Journal and its Editorial Staff functions. A new Bylaw specified that Past Presidents are HONORARY MEMBERS of the Council. The Council remains as the governing body of the Association. But today, for instance, the membership rather than the Council accepts new members by election. Members are still dropped, as they were by Council in 1917, and subsequently, for non-payment of dues. In the Bylaws back then, but not today, there was the provision that "failure of an active member to offer a paper at least once in three years shall be equivalent to resignation." The Councils of today continue to abide by the principles of the 1917 Constitution

and Bylaws in meeting on matters of policy and Association management prior to the Annual Meeting and to be reciprocally active with the membership during the Business Meeting of the Association. During the 1915 Meeting of Council, and because Dr. Webb was so convincing in his view of growth in membership and expansion of the Association, the Council appointed him as "Chairman of a committee of six to influence physicians whose qualifications entitled them to membership in the Association." Qualified, based on professional credentials and experience, may have been implied by Council in its mandate, then, as it is today. Nevertheless, Dr. Webb and his successors on "membership committees" managed to recruit and accept an average of 12 qualified members per year, 1914-1938, so that after 25 years the Association roster consisted of 275 Active Members. As then, members are required to pay an annual administrative dues and are obligated to subscribe to the JOURNAL OF IMMUNOLOGY.

The first Bylaw of the Association specified that a regular meeting of the Association shall be held annually and, according to Bylaw 3, shall be open to all members of the Association. Today, the scientific meetings are open, as well, to non-members and guests. The 1914 and 1915 meetings of the Association were one-day affairs, with morning, afternoon and evening sessions, including the President's Address which remains as an annual tradition. Thereafter, except for 1919, the duration of meetings was extended to two days of scientific sessions. From 1920 to 1937, the Association's meetings were scheduled so that they would coincide with one of the days of the meeting of the American Association of Pathologists and Bacteriologists (AAPB) for a conjoint session. One of these, in 1934, was convened in Toronto, Canada and well received by Canadian colleagues. During the 1938 meetings of the Council and the membership-at-large, a decision was reached by 90% of the members to meet with FASEB in 1939 and to convene a joint session with the American Society of Experimental Pathologists (ASEP). Interpreting the intent of the Council then, it seems that intersocietal THEME symposia (now common to the FASEB Annual Meeting) had their origin. In Council's view, the experience of 1939 could be the compelling or dissuading influence for future conjoint meetings.

Fiscal prudence and responsibility are evident in the ability of the Council to operate administratively on income received from an administrative dues assessment of ONE dollar per member! Over the twenty-five year interval, the administrative dues were raised to only \$2 and then dropped to \$1.50 in 1925. The obligatory annual subscription to the JOURNAL OF IMMUNOLOGY began at \$4, and was raised to \$5 in 1922, and to \$6 per year in 1925 only because the Journal was expanded from one volume and six issues per year to two volumes annually, each with six issues. And, instead of a total annual dues/obligatory subscription assessment of \$8 per member, Council decreased the administrative dues from \$2 to \$1.50 based on "the Treasurer's belief that the business of the Association can be conducted upon an allowance of \$1.50 per member!" The Journal was not without periods of deficit finances, however. After one year of operation, Dr. Arthur F. Coca, the first Editor-in-Chief, informed Council of a 1917 deficit of \$500 but, "not to worry" because through the generosity of Mrs. Harriman of New York, that amount was readily covered. Six years later there still was indication of an annual Journal deficit. It was then, in 1923, that Council agreed to accept contributions from philanthropic and academic sources toward defraying these deficits. But, the fiscal horizon of the Association and its Journal became much brighter by 1930 when the Treasurer reported an Association cash reserve of \$1,216.29 and an additional \$246.40 from Waverly Press, representing the Association's share of the profits from the Journal for 1929 -- the first profit on

record in 13 years. In 1931, the annual Journal page restriction of 500 still prevailed but, the subscription rate increased from \$3.00 to \$3.50 per volume/6 issues engendered primarily because of "excess tabular material" in papers accepted for publication. Rather, than charge all authors a flat per page charge, the Council endorsed the plan of Waverly to charge authors with excess tabular material at \$9.50 per 10 page article.


Based on the "moderate surplus" accrued in the Treasury, the Council, in 1932, assumed a modest role in philanthropy. A contribution of \$100 was made to the Union of Biological Societies (UBS) toward the support of Biological Abstracts. In 1933, \$350 was transferred to the Journal Fund toward paying for additional space "to diminish the number of manuscripts awaiting publication!" And, another \$100 was given to UBS for the same purpose as in the preceding year.

On several occasions, issues arose where Council recognized the need for authoritative intervention. In 1926, for instance, the Council reacted negatively to a suggestion for establishing a Committee of the Association "designated to standardize the procedure of testing the protective power of antipneumococcus sera with mice." Council's view then was that "no society should assume to dictate the selection of the scientific method." A year later, 1927, the Council adopted a National Research Council RESOLUTION and recommended its ratification by the membership for acceptance of the Landsteiner system of O, A, B, and AB blood grouping rather than the two numbering systems of Jansky and Moss, which were believed to create confusion of blood isoagglutinins. And, so it was done. Then there was the proposal of the 13 month calendar -- each month with 28 days -- by the National Committee on Calendar Simplification to which Council reacted with an instruction to the Secretary "to ignore the communication!" In 1934, Council approved a letter to be addressed to the President of the United States expressing the Association's "disapproval of the withholding of funds from the Surgeon General's Library (SGL) by the Government." Council's action was influenced by a request from the SGL for a "donation of a subscription to the Journal" because of lack of funds in the SGL. Even though on two previous occasions the Council had been generous in contributing to the support of Biological Abstracts, Council at its 1937 meeting rejected an audacious suggestion of a constituent to assess each Association member for \$2 toward the annual support of the publication. That action was followed by another disapproval of a proposal by the Medical Libraries Association for publication of a journal of clinical abstracts.

Perhaps, it was accrued experience and intense desire among the early leaders of the Association that motivated them to manage so capably and to effectively implement the thrusts and strategies of the new scientific society. Presidents H. Gideon Wells (1923), Ludvig Hektoen (1926), and Eugene L. Opie (1928) served, in prior years, as Presidents of both the AAPB and ASEP. Drs. Frederick G. Novy (1924) and Augustus B. Wadsworth (1932) came with previous experience as the Presidents of ASEP and AAPB, respectively. Notwithstanding is that, after their AAI Presidencies, Drs. William H. Park (1918) and Alphonse R. Dochez (1931) were elected to that Office of the ASEP and Drs. James W. Jobling (1915), Hans Zinsser (1919), Oswald T. Avery (1929) and Stanhope Bayne-Jones (1930) served as Presidents of the AAPB after holding that Office in AAI.

Although brief, but nevertheless to the point, the Minutes of the Council Meetings of 1914 through 1938 were recorded with diligence and foresight by the respective

Secretaries of the period. Those historic documentaries made this brief possible. Probably there were many other pertinent and fascinating documents that had been either misplaced or irretrievably lost which could have added substantially to the detail of this summary of the Association's Founding and First 25 years of dynamic Progress!


Joseph F. Saunders, Ph.D.

..... NOTICES OF CONSEQUENCE

BANNER 1988

As President Dr. Shreffler noted, our spirit at AAI/FASEB 1988 will be commemorative of the 75th Anniversary of the Founding of the Association and the BANNER BEGINNING of the fourth quarter of a dynamic organization and, we believe, the second century of a burgeoning science. MEMBER ATTENDANCE and PARTICIPATION at AAI/FASEB 1987 was record-breaking -- 1319 members or 34% of the membership. Certainly, in 1988, we look to your improvement of those figures and your enrichment of the meeting and its significance.

FASEB 1987 DATA

The Total Scientific Registration, for a five Society meeting, was 12,795 -- 5,093 FASEB members, 5,014 non-members and 2,688 students. Adding to the total meeting complement of 16,510 were 2,663 registered exhibitors, 979 guests of scientists and exhibitors and a PRESS registration of 73. AAI's members (1,319) represented 24% of the FASEB member registry; non-members of FASEB Societies registering with prime interest in IMMUNOLOGY totaled 1,322 (26.49%). Thus, with either "dedicated or leaning" interest in IMMUNOLOGY, the registrants amounted to 2,641 or 26.57%! 383 of the scientific registrants neglected to indicate "an interest".

THE FREDERIK B. BANG SCHOLARSHIPS

Applications are solicited for consideration for the 1988 Frederik B. Bang Scholarship Awards for the study of the immunology, pathology and molecular biology of infectious disease of marine invertebrates. The DEADLINE for receipt of applications for 1988 is 1 March 1988. Further INFORMATION and FORMS can be obtained by writing to the Frederik B. Bang Scholarships Program, American Association of Immunologists, 9650 Rockville Pike, Bethesda, MD 20814 or by calling the AAI Executive Office at (301) 530-7178.



THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS
1987-1988 GOVERNANCE

OFFICERS:

Donald C. Shreffler -- President
Max D. Cooper -- Vice President
William E. Paul -- Past President
Lawrence M. Lichtenstein --
Secretary-Treasurer

COUNCILLORS:

G. Jeannette Thorbecke
Alfred Nisonoff
Henry Metzger
Frank W. Fitch

EXECUTIVE OFFICER: Joseph F. Saunders

EDITOR-IN-CHIEF, J. IMMUNOLOGY: Ethan M. Shevach

COMMITTEES

Nominations (1988)

J.W. Uhr, Chairman
M.E. Koshland
H.M. Grey
F.S. Rosen
U. Storb

Status of Women

K. Bottomly, Chair(1989)
S.E. Cullen(1988)
M. Howard(1988)
N.H. Ruddle(1988)
E.S. Metcalf(1989)

Publications

P.P. Jones, Chair(1989)
H.R. Colten(1988)
H.M. Grey (1989)
F.S. Rosen(1989)
S.E. Cullen(1990)
D.M. Marcus(1990)

Membership

J.A. Berzofsky(1988)
Chairman
T.E. Hugli(1988)
S. Vogel(1988)
E.W. Ades(1989)
C. Cowing(1989)
R.T. Woodland(1989)
T.H. Hansen(1990)

Program

R.J. Hodes(1988)
Chairman
M.A. Kaliner(1989)
B.K. Birshstein(1988)
R. Finberg(1988)
H.M. Johnson(1988)
R. Snyderman(1988)
K. Bottomly(1989)
P.D. Greenberg(1989)
M.I. Greene(1989)
J.J. Oppenheim(1989)
R.R. Rich(1990)
J.W. Streilein(1990)
E.S. Vitetta(1990)

Education

C.W. Pierce(1988)
J.A. Kapp(1988)
Co-Chairs
J.H. Wallace(1988)
R.F. Ashman(1989)
D.T. Fearon(1989)
D.W. Scott(1989)
E.G. Engleman(1990)
M. Howard(1990)
J.R. Parnes(1990)
A. Singer(1990)

Awards

R.H. Schwartz(1988)
Chairman
E. Rothenberg(1989)
B.R. Bloom(1990)
M.E. Koshland(1990)

Historian

A.M. Silverstein

Minority Affairs

J.H. Wallace(1988)
Chairman
E.E. Hanna(1989)
R.N. Hiramoto(1989)
H.M. Johnson(1989)
C.F. Merryman(1989)
R.I. Mishell(1989)
C.S. Walters(1989)
C.A. Laing(1990)

Clinical Immunology and Immunopathology

R.R. Rich(1990)
Chairman
J.L. Fahey(1988)
N.R. Rose(1988)
S. Broder(1989)
C.B. Carpenter(1989)
M.M. Frank(1989)
L. Chess(1990)
P.E. Lipsky(1990)
B.D. Schwartz(1990)

Veterinary Immunology

O. Barta(1990)
Chairman
T.C. McQuire, Jr.(1990)
J.A. Roth (1990)
I.R. Tizard(1990)
W.T. Weber(1990)

F.B. Bang Scholarships

A.M. Silverstein
Chairman
A. Bang
M.D. Cooper
E.S. Pendergast
C.L. Reinisch

AAI REPRESENTATIVES TO FASEB COMMITTEES

<u>Federation Board:</u>	W.E. Paul(1988) D.C. Shreffler(1989) M.D. Cooper(1990)	<u>Education:</u>	D.W. Scott(1990)
<u>Executive Board:</u>	M.D. Cooper(1990)	<u>Public Affairs:</u>	W.H. Stone(1990)
<u>Finances:</u>	A. Nisonoff(1990)	<u>Public Information:</u>	M.E. Weksler(1989)
<u>Program:</u>	J.F. Saunders	<u>Publications:</u>	F.P. Inman(1989)
<u>Meetings:</u>	F.L. Owens(1988) R.J. Hodes(1988)	<u>Life Science Research:</u>	D.S. Singer(1990)
		<u>Summer Conferences:</u>	K.S. Smith(1988)

AAI REPRESENTATIVES TO ORGANIZATIONS

IUIS Council..... M.D. Cooper(1989)
IUIS Nomenclature Committee..... C.H. Morse(1989)
AMERICAN TYPE CULTURE COLLECTION..... R.G. Mage(1989)
Eli Lilly Committee on the ASM..... S.S. Tevethia(1988)
NCISD Scientific Advisory Board..... B.R. Bloom(1989)

..... THE CONSTITUENCY WHO'S WHO

IOM MEMBERS

Recently elected to membership in the INSTITUTE OF MEDICINE, National Academy of Sciences, were Drs. Anthony S. Fauci (AAI 73), Joseph M. Davie (AAI 72) and Adel A.F. Mahmoud (AAI 76).

AWARDS

Dr. Joost J. Oppenheim (AAI 68), Chief, Laboratory of Molecular Immunoregulation, NCI, was recently distinguished as the recipient of the AVERY-LANDSTEINER-PREIS 1987 Award, bestowed by Die Gesellschaft fur Immunologie, Germany. The award is granted to scientists who are outstanding internationally.

Dr. Steven A. Rosenberg (AAI 72), NCI's Chief of Surgery, recently received the GAMBRO Award of the International Society of Blood Purification. The award is a contribution of GAMBRO AB, a Swedish firm with interests, among others, in the advancement of immunotherapy.

Dr. Philip H. Abelson, a good friend of the Association and former Editor of SCIENCE Magazine, was presented recently with the NATIONAL MEDAL OF SCIENCE by President Ronald Reagan.

ACHIEVEMENTS

Dr. Frank Lilly (AAI 80), Chairman of the Genetics Department, Albert Einstein College of Medicine, Bronx, NY, has been appointed by President Reagan to membership on the PRESIDENTIAL COMMISSION ON AIDS.

Dr. Heinz Kohler (AAI 71) is now the DIRECTOR OF RESEARCH of IDEC, INC., a biotechnology company, in La Jolla, CA, engaged in developing specialized anti-antibodies for pharmaceutical use. Dr. Kohler's previous position was with Roswell Park Memorial Institute as Director of the Department of Molecular Immunology.

Dr. Bernard W. Janicki (AAI 70) has been named DIRECTOR FOR RESEARCH of the Dana-Farber Cancer Institute, Boston. While in the service of NIAID, Dr. Janicki was one of the principals in the evolution of the traditional AAI-NIAID Symposium on "Contemporary Topics in Immunology".

Dr. Joseph M. Davie (AAI 72) recently acceded to the post of SENIOR VICE PRESIDENT, Preclinical Research, Searle Research and Development Division, G.D. SEARLE & CO., Skokie, IL. Previously, Dr. Davie was the Chairman, Dept. of Microbiology and Immunology, Washington University, St. Louis.

Dr. Enrico Mihich (AAI 72), Director, Grace Cancer Drug Center, Roswell Park Memorial Institute, Buffalo, has assumed the PRESIDENCY of the American Association for Cancer Research.

Dr. Robert M. Nakamura (AAI 69), Scripps Clinic and Research Foundation, will conduct a one day program on IMMUNOLOGY PERSPECTIVES AND HORIZONS presented by St. Luke's Hospital Laboratory Education Series, 19 September 1987, St. Luke's Hospital of Kansas City, Missouri.

BEYOND THE CALL

Association members continue to responded with VOLUNTARY FINANCIAL CONTRIBUTIONS which certainly help in the support of AAI's goals and innovative activities. We greatly acknowledge the recent generosity of Doctors:

Toni N. Mariani
U. Minnesota

Wolfgang Leibold
Hannover, FRG

O. Ayandar-Batuman
NJ Medical School

MEMBERS EMERITUS

It was indeed a pleasure to receive communications from DR. THOMAS P. MAGILL (AAI 37 and President 1953-54), DR. CHARLES WEISS (AAI 20), and Dr. LEO H. CRIEP (AAI 38). From Dr. Weiss, "..... I searched for relics of the AAI, but could find nothing. However, there are a few historical items that may be of interest to you I was the FIRST AND ONLY graduate student in immunology (1918) at the Univ. of Penna. Graduate School of Med. and Dr. John A. Kolmer (AAI President 1917-18) and Dr. Allen J. Smith gave me my Ph.D....." Dr. Crip wrote, "..... Tell me whether you may wish Dr. Arthur F. Coca's original book which still includes a great deal of wisdom". Dr. Magill was beautifully apologetic in not being able to provide the AAI with an "abundance of historic of treasures".

Our congratulations go to DR. FRANK ADLER (AAI 53), DR. JOAN WRIGHT GOODMAN (AAI 66), DR. PERCY MINDEN (AAI 69) and DR. ROBERT M. STROUD (AAI 69) on their transfer to MEMBER EMERITUS status and their having achieved this milestone in their rewarding professional careers.

IN MEMORIAM

We all grieve from the recent loss of friends and colleagues of long standing. Condolence, on behalf of the Council and Members of the Association, has been expressed to their families and their immediate associates.

Dr. WERNER HENLE, a member of the AAI since 1938 and President, 1962-1963 In collaboration with his wife, Dr. Gertrude Henle, he had made singular contributions to immunologic science during the past half century discovery that Epstein-Barr virus is the cause of infectious mononucleosis the results of their studies of viral immunopathogenesis contributed to the development of immunization methods for the prevention of mumps and influenza Werner and Gertrude Henle contributed more than 400 publications of importance. Their basic research into the mechanisms of viral infections led to the explanation of disease states — such as latency and persistence of infection — and the phenomenon of viral interference, making possible the discovery of interferon.

Through correspondence, in quest of AAI Archival contributions, we learned of the

recent demise of Dr. WILLIAM C. BOYD (AAI 33 and President 1959-60), Dr. CORA M. DOWNS (AAI 29) and Dr. DON R. MATHIESON (AAI 46).

Last month, the Association lost a colleague and a friend in the FASEB Corporate, Dr. KENNETH M. ENDICOTT, retired Executive Officer of AAP (1986) and Executive Director of the Universities Associated for Research and Education in Pathology. Dr. Endicott was most generous to "that new AAI Executive Officer down the block" with counsel, guidance and historic facts, but most important, cordial collegiality!

..... KNOWING OUR CORPORATE ASSOCIATES

PPG INDUSTRIES, INC., CHEMICALS GROUP

Pittsburgh, Pennsylvania

Corporate Representative: Dr. P.M. Chakrabarti

Through our support of the Research Institute of Scripps Clinic (RISC), we are supporting basic research in molecular and cellular immunology. Our most important effort is the identification of new commercial opportunities made possible by developments in immunologic science. The focus of our current collaborative programs at RISC and of the PPG scientists is the application of current and evolving immunologic science in biotechnology. Included in these efforts is the application of antibodies for epitope mapping, molecular structure determination, and molecular design. In the area of immunochemistry, we are evaluating applications of antibodies recognizing organic molecules, and are researching their uses in diagnostics, immunoadsorption, and catalysis. Maximizing antibody functionality for these applications is a major challenge that involves investigation of antibody immobilization chemistry, substrates for immobilization, and antibody modification.

WAVERLY PRESS, INC.

Baltimore, Maryland

Corporate Representative: Constance B. Kiley

Waverly Press is pleased to be a Corporate Associate Member of The American Association of Immunologists. We are proud to be part of the support effort that contributes to its growth and success. Our relationship had its beginnings as a result of the socio-economic climate created by World War I. There was a shortage of European publications and a demand for American science journals. Waverly, then known as Williams & Wilkins, had evolved from its 1890 beginnings to meet the needs of the time and was pursuing this scientific market. These conditions led to the 1916 relationship between Waverly and the Association for the printing and publishing services of THE JOURNAL OF IMMUNOLOGY. Waverly understands that immunology is vital to the biomedical community. In addition to supporting publishing efforts, Waverly

has encouraged research in biomedical science through the establishment of the Passano Foundation, which presents an award, each year, to a person or persons who have made an outstanding contribution to the advancement of biomedical science in the United States. Past laureates in the immunologic field have been AAI Past President DR. OSWALD T. AVERY (1949 awardee), AAI Past President DR. STANHOPE BAYNE-JONES (1959), AAI Past President DR. KIMISHIGE ISHIZAKA and DR. TERUKO ISHIZAKA (1972 recipients), AAI President DR. HENRY KUNKEL (1975), and AAI President DR. HUGH O. McDEVITT (1981). We have a special appreciation of our lasting affiliation with AAI and its science and look forward to continued future endeavors.

SMITH KLINE & FRENCH LABORATORIES

Philadelphia, Pennsylvania

Corporate Representative: Dr. George Poste

SK&F Laboratories contributes extensive research efforts in molecular immunology and immunopharmacology with its primary objectives being the design of novel therapies for immune- and nonimmune-mediated chronic diseases. The research is matrix-structured and integrates the Departments of Immunology, Molecular Genetics, Protein Biochemistry, Peptide Chemistry, Medicinal Chemistry, Pharmacology and Molecular Pharmacology. Research activities include studies of phospholipid metabolism in inflammation and cell activation; identification of receptor antagonists and/or agonists for immunoregulatory cytokines; characterization and gene cloning of novel lymphokines that enhance resistance of immunocompromised hosts against infections; induction of suppressor cells in therapy of autoimmune diseases; definition of ligand-receptor interactions on lymphocyte subsets resulting in regulation of specific lymphocyte functions; and, application of antiidiotype strategies to receptor studies and the drug discovery effort.

MCNEIL PHARMACEUTICAL

Spring House, Pennsylvania

Corporate Representative: Dr. Edward S. Kimball

McNeil Pharmaceutical has had a long-standing commitment to the discovery and development of drugs which will alleviate and control acute and chronic inflammation. Accordingly, a commitment was made to support the basic biologic research programs necessary to provide a greater comprehension of the mechanisms which underlie the clinical symptoms of inflammation and autoimmune disease, and to coordinate these basic research programs with rational drug design programs. Immunopharmacology research at McNeil includes basic and applied research programs in hypersensitivity research for studying the control of immune function and mediators such as arachidonic acid metabolites, enzymes, growth factors and other cytokines, such as interleukin-1, that are involved in chronic inflammation and tissue destruction. With the recent integration into the Janssen Research Foundation, Worldwide, the role and mission of immunopharmacology research at McNeil

Pharmaceutical has been expanded in order to accommodate an intensified effort to study immunonormalizing and immunorestorative mechanisms involved in the control of autoimmunity and immunodeficiency disease.

IMCLONE SYSTEMS INCORPORATED

New York, New York

Corporate Representative: Dr. Samuel D. Waksal

ImClone Systems Inc. was founded in April 1984. The focus of the company is the development of products for the infectious disease market utilizing expertise in immunology, molecular biology and molecular modeling. ImClone's product development strategy is to target single disease entities (such as hepatitis) or groups of related diseases (such as sexually transmitted infections) and produce a spectrum of diagnostic and therapeutic products. ImClone has selected infectious disease entities for development of complete panels of products for diagnosis, treatment and prevention. Current work is being done in viral-related liver disease (such as hepatitis B), sexually transmitted disease (such as AIDS) and enteric pathogens. Within each group, product development strategy has dictated that the company achieve a balance between products that can enter existing markets and those aimed at markets that are emerging or do not yet exist.

..... POSITIONS AND OPPORTUNITIES

NIAID PROGRAM DIRECTOR, Acquired Immunodeficiency Syndrome Program (AIDSP) The position is one of four extramural program director positions in the NIAID, its incumbent being responsible for providing leadership and direction in the planning and administration of a national program of research grants and contracts in AIDS and the related science disciplines of immunology, microbiology, virology and parasitology. Responsibilities also include planning, directing and coordinating an international collaborative program in AIDS research. The incumbent will formulate the major overall policies for the AIDSP and advise the Institute Director of trends and developments in the Program as they relate to the NIH/PHS/DHHS, other Federal Agencies and related group CLOSING DATE IS 15 SEPTEMBER 1987..... CONTACT: Mrs. Janice R. Lacy, NIAID Personnel Officer (301) 496-4634.

CELLULAR IMMUNOLOGIST (M.D. or Ph.D.) at Junior Staff Level wanted for immediate opening with Clinical Immunology group studying human autoimmune disease. Experience with flow cytometry, cell sorting and cloning of B Cells required for in vitro studies of rheumatoid factors RESUME TO: Dr. Vincent Agnello, Director, Clinical Immunology Laboratory, LAHEY CLINIC MEDICAL CENTER, 41 Mall Road, Box 451, Burlington, MA 01805.

CANCER PREVENTION FELLOWSHIP PROGRAM..... The Division of Cancer Prevention and Control, NCI, NIH, is accepting applications for the Program Deadline for receipt of applications is 15 January 1988 The primary purpose of this program is to attract individuals from a multiplicity of health science disciplines into the

field of cancer prevention and control research POSTCARD to NIH/NCI/DCPC/CCAB, 9000 Rockville Pike, Blair Building, Room 4A05, Bethesda, MD 20892-4200 or CALL (301) 427-8788.

..... NEW IN IMMUNOLOGY

The Congratulations of the AAI Council and membership to President pro-tem, Dr. Bruce S. Rabin, on the formation on 3 May 1987 of the ASSOCIATION OF MEDICAL LABORATORY IMMUNOLOGISTS (AMLI). "The AMLI will primarily direct its attention to the aspects of medical immunology that are laboratory based. Some specific areas of interest..... are quality control, standardization, test development, test automation, robotics and computerization..... in addition to an annual meeting, regional workshops may be held....." The Administrative Office is located at 5725 Children's Place, Pittsburgh, PA 15213-3417.

Dr. J. Wayne Streilein (AAI 68) and his associates are creating a new Journal entitled REGIONAL IMMUNOLOGY. Dr. Streilein will serve as Editor-in-Chief, the Editorial Office will be in Miami, and John Wiley and Sons, Inc. will publish the Journal. Dr. Streilein has enlisted the support of an outstanding cadre of immunologic scientists for service on the Advisory Committee, as Section Co-editors and the Editorial Board. Creation of this new Journal coincides with the Association's inclusion, for 1988, of a new Scientific Program BLOCK (topics 2024-2031) entitled "Regional Immunology". "The Purpose of this Journal is to provide a focus for the judicious dissemination of results of experimental studies of immune reactivities as they are induced, expressed, and regulated in different regions of the body..... mucosal surfaces; skin and appendages; eye, brain, lung, genitourinary tract, endocrine glands, and others....."

..... FROM THE ALLIED SECTOR

The 1986 Report of the AMERICAN ASSOCIATION OF BLOOD BANKS, recently, received is quite descript of AABB's activities related to the AIDS problem..... Transcripts from the conferences on "Legal Issues in Transfusion Medicine and Current Status of HLV-III Testing" were published..... AABB commissioned a nationwide public opinion poll in December 1985. Of 1005 persons surveyed by telephone, 34% thought it was "likely" one could get AIDS by donating blood; 53% thought it "likely" one could get AIDS from a blood transfusion; and only 46% were aware that blood was tested for evidence of AIDS infection..... Many items on AIDS, on surrogate testing for Non-A, Non-B Hepatitis, and other immunologic interests are included in the AABB Report..... One particular item not to be overlooked is the AABB's KARL LANDSTEINER MEMORIAL AWARD.....

The PHARMACEUTICAL MANUFACTURERS ASSOCIATION Quarterly Newsletter, QUALITY CARE INSIGHTS, Vol. 1, No. 2, Summer 1987 contains an excellent two-page chart on "AIDS

Products in Development." Listed are 17 antiviral drugs, 13 immunomodulators and 5 vaccines, as well as 14 diagnostics. In addition to the brand, generic or experimental code name of each, the manufacturers are listed, treatment indications of each agent and the stages of their development. Indications of disease applicability of the developmental agents is not limited to AIDS, but include as well the opportunistic diseases such as Kaposi's sarcoma, *Pneumocystis carinii* and the AIDS-related complex. PMA is located at 1100 Fifteenth Street, N.W., Washington, DC 20005.

..... OFF THE LITERARY SHELF

RECOMBINANT LYMPHOKINES AND THEIR RECEPTORS, Ed.: Steven Gillis (AAI 81), Executive Vice President and Director, R&D, IMMUNEX CORPORATION from Marcel Dekker, Inc., New York..... "Focusing on the isolation and characterization of genes that encode proteins responsible for tumor cell destruction, this timely reference presents valuable new methods for producing recombinant soluble mediators of the immune response..... With contributions by nearly 60 international authorities, this volume reviews the experiments which allowed for the successful production of recombinant interferon...surveys the cloning and expression of human IL-2...explores the theories of the mechanisms behind induction of IL-2 responsiveness in a wide variety of cell types...and describes the use of cross-species hybridization for the isolation of a bovine IL-2 cDNA..... Additionally, the book updates the experiments that led to the isolation of human IL-2 cDNA and its expression in mammalian cells...chronicles an investigation that resulted in the successful molecular characterization of the murine IL-2 receptor...looks at how interleukin-1s, α and β , appear to bind to the same high-affinity cell-surface receptor...considers the isolation of the gene for murine interleukin-3 (IL-3)...and much more."

BIOCHEMISTRY AND MOLECULAR GENETICS OF CANCER METASTASIS, Eds.: K. Lapis (Semmelweis Med., Univ., Budapest), L.A. Liotta (NCI,NIH) and A.S. Rabson (NCI,NIH)..... from Kluwer Academic Publishers, Norwell, MA..... "Approximately 50% or more of patients with primary malignant neoplasms already have established metastases. Consequently, the most important problem in cancer treatment is the destruction or prevention of metastases. Research on these processes has obvious clinical importance. Yet it has only been recently that investigators have attempted to study the mechanisms involved in this process. This is in part due to the complexity of metastases formation. It is expected that multiple biochemical factors and gene products derived both from the host and the tumor cell may be required for the metastasizing tumor cell to invade, survive host defenses, travel in the circulation, arrest and adhere in the target organ, invade out, and grow as a metastatic colony. Some of these factors have recently been indentified by investigators who have focused on individual steps in the metastatic process and have employed new technologies in immunology, biochemistry and molecular biology. The purpose of this book is to capture some of the excitement in the field of metastases based on new discoveries and to translate these discoveries into widely adopted clinical methods for the prevention, detection, and eradication of metastases".

NEUROREGULATION OF AUTONOMIC, ENDOCRINE AND IMMUNE SYSTEMS, Eds.: R.C.A. Frederickson (Monsanto Company), H.C. Hendrie (U. Indiana), J.N. Hingtgen (U. Indiana) and M.H. Apriso (U. Indiana)..... from Kluwer Academic Publishers, Nowell, MA..... "The content is detailed with respect to the: I. Central Neurotransmitter Systems..... II. The Autonomic System..... III. The Neuroendocrine System..... IV. The Immune System..... V. The Central Nervous System and Disease. This book is a unique resource for understanding the interaction between the central nervous, autonomic, neuroendocrine and immune systems. Including contributions from such renowned experts in the field as Tomas Hokfelt, Floyd E. Bloom, and Herbert Weiner, it provides a fascinating insight into how the scientific exploration of these systems relates to the etiology of disease and its treatment. The editors provide the reader with an excellent means of applying laboratory findings to medical practice by following each basic science presentation with pertinent clinical data. Neurobiologists, immunologists, psychiatrists, cardiologists, students and other will all benefit from this important and informative text.

IMMUNOLOGY OF ENDOCRINE DISEASES, Ed., A.M. McGregor (U. of Wales, UK)..... from Kluwer Academic Publishers, Nowell, MA..... This book is the first in a major Immunology and Medicine series. The material presented will cover the broader areas of clinical immunology thereby enabling the readers to apply the information to their own sphere of medical practice. Each book in the series will be completely up-to-date as it will be written by immunologists who are actively involved in the field of clinical medicine or pathology. For the clinician with little or no formal immunological training, IMMUNOLOGY OF ENDOCRINE DISEASE is a book written by immunologists specifically to explain the pathogenesis and aetiology of autoimmune endocrine disease. Basic concepts and recent developments are covered in a manner which will be readily comprehensible to the clinician, to diabetologists, endocrinologists, and to general practitioners."

..... LEGISLATIVE ASSETS AND LIABILITIES

From Martha F. Cleveland's SUMMARY OF LEGISLATION (FASEB Office of Public Affairs)..... Rep. Robert C. Smith (R-NH) has introduced HR 2883 on 1 July 1987 which would require NIH to transfer the so-called Silver Spring Monkeys to Primarily Primates, Inc..... Rep. Barbara Boxer's (D.CA) HR 1635 would prohibit the use of the LD 50 test to fulfill federal product safety, labeling and transportation requirements for Consumer products..... HR 1770, introduced by Rep. Charlie Rose (D-NC), would amend the Animal Welfare Act to allow a private citizen "to commence a civil action on his own behalf or on behalf of any animal protected by this Act" In theory the bill would authorize suits only against the federal government A bill (HR 78), introduced by Rep. Robert J. Mrazek (D-NY) and titled "Pet Protection Act", would make researchers ineligible for NIH federal funds if they obtained or used pound or shelter animals for any research purposes, whether federally or privately funded..... Sen. Pete V. Domenici (R-NM) introduced S 1480, Human Genome Mapping, a section of which would require the Secretary of Energy to establish a Human Genome Consortium consisting of universities, private industry and government agencies for: creating a physical map of the human genome; integration of information derived from efforts in gene mapping; location of genes and other markers on the maps; produce and distribute DNA sequences needed by the research community;

and develop automation, robotics, and computer facilities for these purposes.

HR-2626, introduced by Rep. Charles B. Rangel (D-NY) and S-1220, by Sen. Edward M. Kennedy (D-MA) both relate to AIDS EDUCATION, TRAINING AND RESEARCH. The bills' provisions include: 1) a directive to NIH to devise a National Program on AIDS to include "an expanded, intensified, and coordinated research program" and demonstration, education and other programs for the detection, diagnosis, prevention and treatment of AIDS; 2) the designation of one of the institute directors as AIDS Coordinator who will implement a plan "to expedite the award of grants, contracts, or cooperative agreements" for projects relating to AIDS, including individual investigator-initiated research grants not in response to a solicitation for proposals; 3) an outline of the AIDS Coordinator's authority, which includes expanding clinical trials of treatments and therapies, establishing or supporting large-scale production or distribution of specialized biological materials and other therapeutic substances, improving or repairing research facilities and making grants for the renovation of facilities; 4) the establishment of a National AIDS Advisory Board within NIH to review and evaluate the implementation of the National Program on AIDS; 5) the establishment by the NATIONAL INSTITUTE ON ALLERGY AND INFECTIOUS DISEASES of AIDS research centers and virus and serum bank in which all human immunodeficiency virus serotypes and serum are available to qualified investigators and organizations.

Other legislation introduced include S-1176 by Sen. John C. Danforth (R-MO) on "Research Facility Bonds — tax exempt bonds issuance by private colleges and universities..... HR-1990 by Rep. Bob Dornan (R-CA) to "Regulate Fetal Tissue Transportation and Storage"..... and HR-1905 by Rep. Robert A. Roe (D-NJ) creating a university facilities repair, renovation and replacement program within the NSF.

..... WITHIN THE HHS

The FOOD AND DRUG ADMINISTRATION has proposed to exempt with some limitations, 21 clinical chemistry and clinical toxicology devices from the requirement of premarket notification [510(k)]. In case it was missed, the proposal was published in the Federal Register on 1 May 1987.

A short time ago, the FDA announced that it was allowing the NCI, NIH to expand the use of two experimental cancer therapeutic agents. These are INTERLEUKIN-2 (IL-2) combined with lymphokine-activated killer (LAK) cells and IL-2 alone. These would be available to patients with advanced melanoma or advanced kidney cancer at NCI-supported clinical and comprehensive cancer centers.

In mid-June the FDA began Action Plan Phase II which includes, among others the following goals: (1) provide the highest priority review to AIDS-related products; (2) strengthen post-marketing surveillance activities to detect quickly any unexpected risks.....; and (3) undertake several "Commissioner's Special Initiatives such as..... products for RARE DISEASES.....

HHS Secretary, Otis R. Bowen, announced a revision of FDA regulations so that promising experimental drugs might be readily available for treating patients with serious or immediately life-threatening diseases such as AIDS..... "Serious" diseases

include, for example, Alzheimer's, advanced multiple sclerosis..... progressive ankylosing spondylitis, active and advanced LUPUS and certain forms of epilepsy and diabetes.

..... INSIDE THE NATIONAL ACADEMY

An INSTITUTE OF MEDICINE "Report of a Study -- Causes and Consequences of Alcohol Problems" calls our attention to the known and potential effects of alcohol on the immune system such as the migration of lymphocytes, circulating suppressor/cytotoxic lymphocytes and natural killer cell activity. The relationship of alcohol to infectious diseases and AIDS is reviewed. An agenda for research is addressed.

CHINA-STUDY GRANTS..... The Committee on Scholarly Communication with the People's Republic of China has announced opportunities for graduate students and scholars for 1988-1989. Grants are offered for long-term study and research at Chinese universities and research institutes in the social sciences and humanities. Short-term visits for scholars in all disciplines are available. Applications must be received by 10 October 1987. Further information can be obtained by calling (202) 334-2727.

..... INTERNATIONAL NOTES

In WORLD HEALTH (June 1987), the WHO reports that, as of 26 February 1987, 41,919 cases of AIDS were reported from 91 countries, representing all continents..... The Americas: Of the total of 34,195 cases reported, 30,632 (90%) were from the United States, where the "classic" epidemiology of the disease was first described. According to WHO, the USPHS predicts 270,000 AIDS cases in the US by 1991..... Europe: 25 countries and a total of 4,590 cases with the highest number, 1,253, in France and an European estimate of 30,000 cases by the end of 1988..... Asia: HIV has just started to appear..... Oceania: so far all are from Australia (382) and New Zealand (22)..... Africa: WHO states that "no area of the world appears to be more affected by HIV than Africa, in terms of the proportion of the healthy population already infected and probable numbers of AIDS cases".

From the WHO MEDIA SERVICE..... "WHO is concentrating its efforts to prevent the catastrophic health consequences of drug abuse..... the number of cocaine abusers is put at 4.8 million, of opium abusers at 1.7 million, and of heroin abusers at 750,000 according to UN figurers..... the development of 'designer drugs', made through the tampering of legally permitted compounds, has also added to catastrophic situation. The synthetic formulations have an addictive impact as much as a thousand times more than natural, plantbased substances..... the significance of this public health burden has been further highlighted by the lethal contribution of AIDS....."

From the CHINESE MEDICAL JOURNAL (Beijing, PRC)..... Opsonization Activity in Subacute Hepatic Failure and Chronic Liver Disease (Vol. 100, No. 2, Feb. 1987 of the Chinese Medical Journal) "Opsonin indices were significantly reduced in hepatic failure and severe chronic active hepatitis....." more..... Dot-ELISA in the Diagnosis of Schistosomiasis..... "The results with sera from 63 schisto patients, 65

normal controls and 83 cases with parasites other than schisto indicate no false positives in the 65 controls while positive rates in the schisto patients ranged from 38.9 to 96.8%, depending on substrate....." In the January 1987 issue, Primary Macroglobulinemia with Myelofibrosis, A Case Study..... In the November 1986 issue, Systemic Scleroderma: A Clinical and Immunologic Study.

..... THE IMMUNOLOGY CALENDAR

18-23 October 1987..... DIAGNOSTIC IMMUNOLOGY, Longboat Key Hilton Inn, Sarasota, FL.....featuring applications of monoclonal antibodies, automated immunoassay, non-radio immunoassay, and nucleic acid probes as diagnostic reagents.....CONTACT: Dr. Harold Comerer, Engineering Foundation Conferences, New York, (212) 705-7835.

23-24 October 1987.....International Symposium on the MOLECULAR BIOLOGY OF THE MAJOR HISTOCOMPATIBILITY COMPLEX OF DOMESTIC ANIMAL SPECIES, Iowa State University.....featuring invited presentations by internationally-recognized authorities on the MHC of swine, cattle, horses and chickens.....CONTACT: Dr. C. Warner, Iowa State University, (515) 294-2570.

30 October - 1 November 1987.....THE SECOND CONFERENCE ON CLINICAL IMMUNOLOGY.....Sheraton-Washington, Washington DC.....Sponsored by the CLINICAL IMMUNOLOGY SOCIETY.....Theme Symposia will deal with: (1) Strategies for Targeting Therapies; (2) Lymphokines; (3) Strategies for Implementing Genes in Therapy; (4) AIDS; (5) Autoimmunity; and (6) Chronic Viral Infections.....A Special Symposium will be devoted to "What is Clinical Immunology?".....25 sessions of Posters and Workshops will relate to the theme topics.....For further information, CONTACT: CIS, P.O. Box 827, Bowie, Maryland 20715.

4-7 November 1987.....SECOND INTERNATIONAL CONGRESS ON CYCLOSPORINE, Sheraton Washington Hotel, Washington, DC.....topics include transplantation; mechanisms of immunosuppression; and autoimmune disease applications.....QUERIES: Dr. Barry D. Kahan, U. Texas Medical School, Houston, (713) 792-5346.

9-11 November 1987.....Second Conference on IMMUNITY TO CANCER, Williamsburg, Virginia.....five sessions of invited papers on: (1) Tumor Antigens and Monoclonal Antibodies; (2) Cells Involved in the Immune Response to Tumor Cells; (3) Regulatory Mechanisms in Immunity and their Implications for Therapy; (4) Biomodulation of Cancer I; and (5) Biomodulation of Cancer II; and a workshop on Ethical, Regulatory and Scientific Issues in Immunotherapy.....CONTACT: Ms. Carole Kirby, BRMP, DCT, National Cancer Inst. Frederick Cancer Research Facility, Frederick, MD 21701 (301) 698-1418.

12-13 November 1987.....The Eastern Pennsylvania Branch of the ASM symposium on RAPID METHODS IN CLINICAL MICROBIOLOGY: Present Status and Future Trends, Philadelphia, PA.....CONTACT: Josephine Bartola, J.D., Bureau of Laboratories, P.O. Box 500, Exton, PA 19341-0500.

14-15 November 1987.....MIDWEST AUTUMN IMMUNOLOGY CONFERENCE, University of Iowa, Iowa City.....Symposia and Poster Workshops with major topics on: (1) Mechanisms for Inducing Tumor Cytotoxicity; (2) Immunoglobulin Gene Repertoire and Regulation; and

(3) B Cell Activation and Differentiation.....MORE FROM: Dr. Thomas L. Feldbush, Department of Microbiology, College of Medicine, U. of Iowa, Iowa City, IA 52242.

16-20 November 1987.....27th Annual Meeting of THE AMERICAN SOCIETY FOR CELL BIOLOGY, St. Louis, MO.....eight MAJOR SYMPOSIA, Mini-SYMPOSIA and POSTER SESSIONS on the most recent developments in all areas of Cell Biology.....CONTACT: Dorothea Wilson or Rosemary J. Simpson, ASCB, 9650 Rockville Pike, Bethesda, MD 20814 (301) 530-7153.

18-20 November 1987.....3rd Southern Foundation Virology & Immunology Symposium on IDIOTYPE NETWORKS & IMMUNE REGULATION II: AUTOIMMUNITY, CANCER, RECEPTORS & VACCINES, San Antonio, TX.....discussions of relatively new studies involving anti-idiotypes and cancer treatment.....PLENARY LECTURES, MINISYMPOSIA and evening POSTER SESSIONS.....QUERIES: UPDATE '87, Conference Concepts Inc., 301 South Frio-Suite 125, San Antonio, TX 78207-4414 (512) 270-4548.

19-21 November 1987.....10th INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND CONFERENCE, Waldorf-Astoria Hotel, New York.....Themes include: Molecular genetics of HLA; Gene expression, tissue distribution and regulation; Structure and function of MHC gene products; MHC and disease; and HLA in medicine.....QUERIES: Bo Dupont, Memorial Sloan-Kettering Cancer Center, (212) 794-6005.

24-26 November 1987.....1st INTERNATIONAL CONGRESS ON AIDS IN ASIA and Other Sexually Transmitted Diseases, Manila, Philadelphia.....Sponsored by the U.S. Naval Medical Research Unit No. 2 and the Philippine Society for Microbiology and Infectious Diseases.....General Topics include Prevention and Public Health, Epidemiology, Immunology, Virology, Clinical Management and Clinical Trials.....ADDRESS the Scientific Program Committee, INFINITY PLUS, INC., 3rd Floor Makati Stock Exchange Bldg., Ayala Ave., Makati, MM, Philippines.

6-10 December 1987.....INTERNATIONAL WORKSHOP ON MONOKINES AND OTHER NON-LYMPHOCYTIC CYTOKINES, Hilton Head Island, SC.....the workshop will focus on the regulation of production, release and action in health and disease of: INTERLEUKIN-1 (IL-1); TUMOR NECROSIS FACTOR (TNF); TRANSFORMING GROWTH FACTOR (TGF-beta); MONOCYTE-derived GROWTH FACTOR (PDGF); COLONY STIMULATING FACTOR (GM-CSF); FIBROBLAST GROWTH FACTOR (FGF); HEPATOCYTE STIMULATING FACTOR (HSF); and INTERFERONS (IFN-ALPHA, beta-2).....Attendance LIMITED to 350 participants.....CONTACT: Dr. Sherwood Reichard, RES Society, Medical College of Georgia, Augusta, GA 30912.

23-26 January 1988.....27th MIDWINTER CONFERENCE OF IMMUNOLOGISTS, Asilomar Conference Center, Pacific Grove, CA..... "Antigen Processing and T Cell Activation" is the THEME with Sessions on: I. Intracellular Compartments; II. Antigen Processing; III. Antigen Presenting Cells; IV. T Cell Activation Molecules; and V. Second Signals in Cell Activation.....PROGRAM and RESERVATION Packets available 16 October 1987 from Mrs. Lyn Buchanan, P.O. Box 221, Mineola, TX 75773.

4-6 February 1988.....THIRD INTERNATIONAL CONFERENCE ON MONOCLONAL ANTIBODY IMMUNOCONJUGATES FOR CANCER, San Diego, CA.....Leading researchers will present the latest results of their clinical trials in man using monoclonal antibodies linked to isotopes, drugs and toxins for cancer therapy and detection.....CONTACT: Office of Continuing Medical Education, M-017, UC San Diego School of Medicine, La Jolla, CA 92093.

11-15 April 1988.....DIRECTIONS IN BIOSCIENCE: A Swedish-Finnish-American Conference, Newark, DE and Philadelphia, PA..... Topics include Regulation of the Immune Response; Molecular Bioenergetics; Biotechnology: Tools and Applications; Regulation of Normal and Abnormal Cell Growth; Human Molecular Genetics; and Frontiers in Neuroscience.....WRITE: Directions in Bioscience, Office of Research & Patents, 101 Hullinkin Hall, University of Delaware, Newark DE, 19716.

17-23 April 1988.....UCLA Symposium on MOLECULAR AND CELLULAR MECHANISMS OF HUMAN HYPERSENSITIVITY AND AUTOIMMUNITY, Keystone, CO.....Organizer, Dr. E. J. Goetzl.....Sessions on: Triggering Events and Consequences; Cellular Constituents and Soluble Signals of Human Immunity; Regulation of Production and Cellular Recognition of Antibodies; Major Histocompatibility Complex and T Cell-Associated Control of Immune Responses; Immunologic Effector Mechanisms; Genetic Markers of Autoimmunity and Inflammatory Diseases; Multiple Immune Networks; Molecular Determinants of Autoimmune Diseases; Genetic Definition and Therapy of Immunodeficiencies; and Specific Mediators and Modulators of Human Immunity..... CONTACT: Office of Directors, UCLA Symposia, MBI, UCLA..... (213) 206-6292.

* 1-5 May 1988.....75th ANNIVERSARY MEETING OF *
* THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS at FASEB *
* 1988, Las Vegas, NV.....AAI will be joined by the *
* other five Corporate Societies of FASEB. *

16-19 May 1988.....FOURTH INTERNATIONAL CONFERENCE ON IMMUNOPHARMACOLOGY, Osaka, Japan.....Scientific Program includes Plenary Lectures, Symposia, Workshops and Poster Sessions. The topics to be covered include basic and clinical immunology, and preclinical and clinical aspects of immunopharmacology.....CORRESPONDENCE: Dr. Ichiro Azuma, Secretary General, Institute of Immunologic Science, Kokkaido University, Sapporo, 060 Japan.

12-16 June 1988.....IVth INTERNATIONAL CONFERENCE ON AIDS, Stockholm, Sweden.....CONTACT: Prof. L.O. Kallings, National Bacteriologic Laboratory, S-105 21 Stockholm.

26 June - 1 July 1988.....NEUROIMMUNOMODULATION.....FASEB Summer Conference, Copper Mountain, CO.....Sessions devoted to: Genetic and Developmental Determinants of Neuroimmunologic Interactions (Day 1); Mediators and Cellular Constituents (Day 2); Cellular Receptors and Transductional Events (Day 3); Viral Neuroimmunology (Day 4) Neuroimmunology of Host Defense and Autoimmunity: Pathophysiology, and Neuroimmunologic Disease (Day 5).....CONTACT: FASEB Summer Research Conferences Office..... (301) 530-7093.

13-17 September 1988.....NINTH EUROPEAN IMMUNOLOGY MEETING, Rome, Italy.....Plenary Lectures, Symposia, Workshops and Poster Discussion Sessions on basic and applied immunology.....CONTACT: Dr. Alessandra Biamonte, Scientific Secretariat, Istituto di Clinica Medica II, University of Rome, Viale dell' Università, 37, 00185 Rome, Italy.

THE ASSOCIATION'S MEMBERSHIP ROSTER
(31 JULY 1987)

REGULAR ACTIVE	3 9 7 7
EMERITUS	1 9 5
HONORARY	3 7
TRAINEE	5 5 2
COPORATE ASSOCIATE	2 5
TOTAL	4 7 8 6

GENERAL MEMBERSHIP BENEFITS

- Right to proffer abstracts/papers for the Annual Scientific Meeting.
- Right to sponsor non-member papers.
- Right to vote in the annual election (mail ballot).
- Right to attend and vote at the Annual Business Meeting
- Right to vote on sundry matters and respond to polls.
- Right to sponsor new members.
- Receive the JOURNAL OF IMMUNOLOGY (obligatory subscription at member rates -- 50% of regular cost).
- Receive the AAI Newsletter.
- Receive the FASEB Journal.
- Receive the FASEB Newsletter.
- Receive the FASEB Directory of Members.
- Privilege to Subscribe to certain Optional Journals of Immunology at reduced rates (25-35% less than regular).
- Reduced registration fees for the Annual Meeting.
- Reduced registration fees for the IUIS Congresses.
- Eligibility for the FASEB Group Insurance Plan and other offered benefit plans.